STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

IMPACT
SENTIMENT
MRK : NYSE
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
IMPACT
SENTIMENT
MRK : NYSE
FDA Approves KEYTRUDA® (pembrolizumab) for Treatment of Patients With Resectable (T≥4 cm or N+) NSCLC in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as a Single Agent as Adjuvant Treatment After Surgery
fda approval
IMPACT
SENTIMENT
MRK : NYSE
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
IMPACT
SENTIMENT
MRK : NYSE
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
IMPACT
SENTIMENT
MRK : NYSE
Merck Highlights Innovative Oncology Portfolio and Pipeline at ESMO Congress 2023 Underscoring Commitment to Advancing Cancer Research and Improving Patient Outcomes Across Multiple Stages of Disease
IMPACT
SENTIMENT
MRK : NYSE
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
clinical trial
IMPACT
SENTIMENT
MRK : NYSE
Merck is Collaborating to Address Antimicrobial Resistance
IMPACT
SENTIMENT
MRK : NYSE
Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Disease-Free Survival (DFS) in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery
clinical trial
IMPACT
SENTIMENT
MRK : NYSE
Merck to Hold Third-Quarter 2023 Sales and Earnings Conference Call Oct. 26
earnings
IMPACT
SENTIMENT
MRK : NYSE
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Stock MRK logo
Merck & Co Inc
NYSE:MRK

MRK Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.